RecruitingPhase 2NCT06456463
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Studying Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stemline Therapeutics, Inc.
- Intervention
- Tagraxofusp(drug)
- Enrollment
- 83 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- University of California, Los Angeles, Los Angeles, California, United States
- Stanford Health Care, Stanford, California, United States
- University of Miami, Miami, Florida, United States
- AdventHealth Cancer Institute, Orlando, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Henry Ford Health System Brigitte Harris Cancer Pavillion, Detroit, Michigan, United States
- Washington University - Siteman Cancer Center, St Louis, Missouri, United States
- John Theurer Cancer Center - Hackensack Meridian Health, Hackensack, New Jersey, United States
- Rutgers Cancer Institute, New Brunswick, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- North Shore University Hospital, Manhasset, New York, United States
- NYU Langone Health, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06456463 on ClinicalTrials.govOther trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07548710Study of SA+X in the Treatment of Newly Diagnosed AMLRuijin Hospital
- RECRUITINGNANCT07183878Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)First Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT04010877Multiple CAR-T Cell Therapy Targeting AMLShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE1, PHASE2NCT06129734Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantBenjamin Tomlinson
- RECRUITINGEARLY PHASE1NCT07126782The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT03222674Multi-CAR T Cell Therapy for Acute Myeloid LeukemiaShenzhen Geno-Immune Medical Institute
- RECRUITINGNCT06513273Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)Gruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT07023588Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseYehui Tan
See all trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) →